04:12 PM EDT, 05/05/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) reported Q1 non-GAAP earnings late Monday of $4.06 per diluted share, down from $4.76 a year earlier.

Analysts polled by FactSet expected $4.25.

Revenue for the quarter ended March 31 was $2.77 billion, up from $2.69 billion a year earlier.

Analysts surveyed by FactSet expected $2.86 billion.

The company adjusted its full-year 2025 revenue guidance to $11.85 billion to $12 billion from $11.75 billion to $12 billion earlier. Analysts expect $11.99 billion.

Shares of Vertex were down 3% in after-hours trading.